Αποτελέσματα Αναζήτησης
1 Φεβ 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
In seriously ill patients with suspected MRSA infection, a loading dose of 25-30 mg/kg (actual body weight) may be considered (CIII). Given risk of red man syndrome and possible anaphylaxis associated with large doses, consider prolonging infusion time 2 h and pre-medication with antihistamine .
29 Νοε 2023 · Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia; Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology and laboratory detection; Overview of antibacterial susceptibility testing; Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics) Skin abscesses in adults: Treatment
1 Φεβ 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia,...
1 Φεβ 2011 · For health care–associated MRSA (HA-MRSA) or CA-MRSA pneumonia, IV vancomycin (A-II) or linezolid 600 mg PO/IV twice daily (A-II) or clindamycin 600 mg PO/IV 3 times daily (B-III), if the strain is susceptible, is recommended for 7–21 days, depending on the extent of infection.
3 Φεβ 2021 · PMCID: PMC8210269. DOI: 10.1093/jacamr/dlaa114. Abstract. These evidence-based guidelines are an updated version of those issued in 2008. They have been produced following a review of the published literature (2007-18) pertaining to the treatment of infections caused by MRSA.
